Published on July 2, 2010 at 12:44 AM
United Therapeutics Corporation (Nasdaq: UTHR) and Lee's Pharmaceutical Holdings Ltd. (HKEx: 0950) announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China. Remodulin is a subcutaneously or intravenously administered prostacyclin analogue for the treatment of pulmonary arterial hypertension. Lee's Pharmaceutical is a leading Chinese pharmaceutical company with both a strong cardiovascular focus and extensive commercialization experience.
"We are delighted to work with Lee's Pharmaceutical as our exclusive partner to bring Remodulin to Chinese physicians and their patients," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. "We believe that Remodulin will be an important addition to the currently available treatment options for PAH patients in China."
"We are excited to be United Therapeutics' partner in China for Remodulin," said Dr. Benjamin Li, Chief Executive Officer of Lee's Pharmaceutical. "We are proud to add this important product to our specialty pharmaceutical portfolio and are anxious to begin the cooperative work with United Therapeutics."
Under the terms of the distribution agreement, Lee's Pharmaceutical will be responsible for obtaining all necessary authorizations to market Remodulin in China, including conducting necessary bridging studies. Upon receipt of marketing authorization and pricing approval, Lee's Pharmaceutical will purchase Remodulin from United Therapeutics at a transfer price agreed to by the parties.
SOURCE United Therapeutics Corporation